27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
These findings support the use of triazole scaffolds as a unique and versatile framework for developing multifunctional anti‐Alzheimer agents with perceived disease‐modifying activity. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Agents currently in use against human immunodeficiency virus (HIV) infection, including the prospects of a vaccine, have focused primarily on destroying or disabling the virus. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Anticholinergic medications (ACh) are frequently prescribed to older adults despite being associated with impaired physical functioning. 2 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
For persons with early-stage sympathetic Alzheimer's disease (AD), including those with mild cognitive impairment and mild congitive dementia stages of the disease with confirmed amyloid pathology, KISUNLA (donanemab-azbt) is a disease-modifying treatment. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Im Zuge der Alzheimerkrankheit lagern sich Beta-Amyloid-Plaques im Gehirn ab. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
To investigate the effect and mechanism of etomidate on attenuating Alzheimer-like neuropathology and cognitive impairment in mice with Alzheimer's disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Alzheimer's disease (AD) manifests as a chronic neurodegenerative syndrome featuring cognitive impairment alongside characteristic neuropathological markers: amyloid-beta (Aβ) plaques and tau-associated neurofibrillary tangles. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Eine Möglichkeit zur Behandlung von beginnenden Alzheimer-Erkrankungen stellten Anti-Amyloid-Antikörper (AK) dar, die die Amyloidablagerungen im Gehirn reduzieren sollen. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
On June 7, 2021, the FDA granted accelerated approval to aducanumab (Aduhelm), the first new Alzheimer's drug approved since 2003 and the first ever approved for a mechanism thought to modify disease course. 3 key findings →
Design: regulatory decision Evidence: preliminary
Full summary, score breakdown and related studies → Original source
An independent US drug-pricing watchdog analyzed how lecanemab's actual price compares to its clinical benefit. 4 key findings →
Design: modelling Evidence: moderate
Full summary, score breakdown and related studies → Original source
Eli Lilly's newer anti-amyloid antibody remternetug showed fast, dose-dependent removal of amyloid plaques in a small early trial: three-quarters of people getting the higher doses had their brain amyloid drop below the threshold used to call a scan 'positive' within about six months. 5 key findings →
Design: RCT Participants: 41 Evidence: early
Full summary, score breakdown and related studies → Original source
Trontinemab is designed with a molecular 'shuttle' that helps it cross into the brain more efficiently than older anti-amyloid antibodies, aiming for faster plaque removal at lower doses. 5 key findings →
Design: phase-2-trial Participants: 13 Evidence: early
Full summary, score breakdown and related studies → Original source
Mivelsiran takes a completely different approach from antibody drugs: it's injected into the spinal fluid and uses RNA interference to tell brain cells to make less of the amyloid precursor protein in the first place, rather than clearing plaques after they form. 5 key findings →
Design: phase-1-trial Participants: 19 Evidence: preliminary
Full summary, score breakdown and related studies → Original source
In September 2024 the SEC announced that Cassava Sciences and three individuals tied to the company agreed to pay over $40 million combined to settle federal charges that they misled investors about a 2020 Phase 2 trial of simufilam. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Elderly patients with AD hypovitaminosis D are at increased risk for hip fracture. 3 key findings →
Participants: 29 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A high incidence of fractures, particularly of the hip, represents an important problem in patients with Alzheimer disease (AD), who are prone to falls and have osteoporosis. 2 key findings →
Participants: 15 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
There is high unmet need in dementia with Lewy bodies (DLB). 4 key findings →
Participants: 159 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The author panel systematically reviewed available clinical trial data detailing aducanumab use in individuals with early symptomatic Alzheimer disease. 4 key findings →
Design: clinical trial Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer’s disease (AD) is the most commonly occurring form of dementia. 4 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Rapamycin, an FDA-approved inhibitor of the mammalian target of rapamycin (mTOR) pathway, has demonstrated promising anti-aging and neuroprotective effects. 4 key findings →
Participants: 23 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Monoamine oxidase B (MAO-B) is a high-density protein located mainly in astrocytes that influences mitochondrial function and transition to astrogliosis. 2 key findings →
Participants: 13 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
BackgroundNon-pharmacological interventions may enhance motor-cognitive integration in prodromal Alzheimers disease (pAD). 5 key findings →
Design: randomized controlled trial Participants: 68 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
ObjectiveTo externally replicate and extend prior findings across two structurally independent healthcare data sources, evaluating whether predominant use of antihypertensive medications that stimulate versus inhibit angiotensin II type 2 and type 4 receptor signaling is associated with risk of incident ADRD. 4 key findings →
Design: cohort study Participants: 1,596,034 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
INTRODUCTIONSleep-dependent memory consolidation is impaired early in Alzheimers disease (AD). 2 key findings →
Participants: 37 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
ObjectiveEffective strategies to prevent Alzheimers disease and related dementias (ADRD) are limited. 5 key findings →
Participants: 9,584 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
9 of the 795 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →